Call for information/EOI for neutralising antibodies

Concepts

• pharmaceutical products
• dhsc
• antibody covid-19 therapies
• antibodies
• further details
• clinical trials
• money solution
• covid-19infection
• emerging market
• long-term

Location

United Kingdom:

Description

DHSC invites suppliers to submit an EOI on neutralising antibodies andbinding site, clinical trials on efficacy, safetyfor preventing or treating COVID-19infection, dose&frequency, formats/routesfor administering to patients, monitoringadverse affects, efficacy against SARSCoV-2 variants, supply availability for 2021-2022 and future years and plans forregulatory approval in the UK, if not yetapproved.

Total Quantity or Scope

The Department is interested in engaging with the emerging market through expressions of interest prior to the publication of a contract notice to findinnovative neutralising antibody COVID-19 therapies that could inform the specification of requirements,conditions of contract and commercial model. Further details of how suppliers may engage with the Departmentare included in section VI.3) (additional information) at the end of this notice. Additional information: Interested parties should submit questions via Atamis. Department welcomes discussions with interested parties on areas provision of a value for money solution for the UK tax payer;creating mechanisms for money solution for the UK tax payer;creating mechanisms (including but not limited to agreements) to secure long-term, guaranteed supply contracts with ‘step-in’ rights in future pandemics

CPV Codes

• 33600000 - Pharmaceutical products

Other Information

** PREVIEW NOTICE, please check Find a Tender for full details. ** This Prior Information Notice has been issued to alert the market for the possible procurement of neutralising antibodies. Suppliers should submit expressions of interest.